Vistagen Therapeutics, Inc. (VTGN) Earnings Call Transcripts

20 earnings calls from February 2022 to September 10, 2026

NasdaqCM US Health Care Biotechnology

About Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc. (VTGN) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqCM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 20 calls on record spanning February 10, 2022 to September 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.

Earnings Call History

EarningsCalls.dev has 20 Vistagen Therapeutics, Inc. earnings call transcripts on record, spanning February 10, 2022 to September 10, 2026. Based on this history, Vistagen Therapeutics, Inc. reports quarterly. The most recent call on file is dated September 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker
VTGN
Exchange
NasdaqCM
Country
US
Sector
Health Care
Industry
Biotechnology
Calls on record
20
First call
February 10, 2022
Most recent
September 10, 2026
Reporting cadence
quarterly
Quarter Date
Shareholder/Analyst Calls Sep 10, 2026 Read transcript →
Special Calls Jun 30, 2026 Read transcript →
Q3 FY2026 Feb 12, 2026 Read transcript →
Q2 FY2026 Nov 13, 2025 Read transcript →
Q1 FY2026 Aug 7, 2025 Read transcript →
Earnings Calls Jun 17, 2025 Read transcript →
Q3 FY2025 Feb 13, 2025 Read transcript →
Q2 FY2025 Nov 7, 2024 Read transcript →
Q1 FY2025 Aug 13, 2024 Read transcript →
Q4 FY2024 Jun 11, 2024 Read transcript →
Q3 FY2024 Feb 13, 2024 Read transcript →
Q2 FY2024 Nov 9, 2023 Read transcript →
Q1 FY2024 Aug 10, 2023 Read transcript →
Earnings Calls Jun 28, 2023 Read transcript →
Q3 FY2023 Feb 7, 2023 Read transcript →
Q2 FY2023 Nov 10, 2022 Read transcript →
Company Conference Presentations Sep 13, 2022 Read transcript →
Q1 FY2023 Aug 11, 2022 Read transcript →
Earnings Calls Jun 23, 2022 Read transcript →
Q3 FY2022 Feb 10, 2022 Read transcript →